Early use (treatment within 24 hours of an acute attack is advisable) of acyclovir, valacyclovir and famciclovir antivirals can reduce the time to virus excretion and pain, and shorten the time to cure of primary and recurrent herpes simplex. 1, primary genital herpes: oral acyclovir 200mg, 5 times daily, or 400mg/dose, 3 times daily; or valacyclovir 1g/dose, 2 times daily; or famciclovir 250mg/dose, 3 times daily, both for 10 days. 2, recurrent genital herpes: oral acyclovir 200mg, 5 times a day, or 400mg/dose, 3 times a day for 5 days; or valacyclovir 500mg/dose, 2 times a day for 3-5 days; or famciclovir 1g/dose, 2 times a day for 1 day, or 125mg/dose, 2 times a day for 5 days. 3, frequent recurrence of genital herpes: for patients with more than 6 episodes per year can be given orally acyclovir 400mg twice daily; or valacyclovir 500mg once daily, 1g once daily if ≥ 10 recurrences per year; or famciclovir 250mg/dose twice daily. The duration of treatment is 4 months to 1 year. However, some patients can still relapse after stopping the drug. 4. Recurrent genital herpes with combined HIV infection: acyclovir 200mg, 5 times daily or 400mg/dose, 3 times daily; valacyclovir 1g/dose, 2 times daily; famciclovir 500mg/dose, 2 times daily, use until all skin mucosal damage is healed. In chronically infected patients with co-infection with HIV, administer oral acyclovir 400-800 mg 2-3 times daily; or valacyclovir 500 mg twice daily; or famciclovir 500 mg/dose twice daily. Prevention Remove or avoid precipitating factors such as exposure to cold, sunlight, emotional stress, etc. whenever possible. During the asymptomatic detoxification period, 70-80% of the herpes simplex virus can be unknowingly transmitted to others. Abstinence is currently the only definitive and effective method of preventing genital herpes. Condoms provide protection against transmission of herpes simplex virus only when they cover all lesions, and are better for susceptible women than for susceptible men. Daily suppressive therapy is recommended for patients with more than six episodes of genital herpes per year, as suppressive therapy reduces the probability of transmission of genital herpes to susceptible individuals by reducing virus excretion during the asymptomatic phase by 95%.